RxDoctor Payments Data

Nicholas Demille

Medical · St George, UTNPI 1821670936

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,580 of the $3,313 with a category attached, or 77.9%. 11 manufacturers reported payments, led by Boston Scientific at 46.5% of the total. Reporting peaked in 2024 at $2,164 and has fallen 61.5% since, to $833 in 2025.

$3,313in general payments, 2019–2025

Across 88 payments — averaging $37.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • AbbVie$641
  • Medtronic$316
  • Pfizer$224
  • Lundbeck LLC$172
  • Spinal Simplicity, LLC$118
  • plus $300 from 5 others

What the payments were for

  • Travel & lodging$73222%
  • Food & beverage$2,58078%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,313 in reported general payments places this provider in the 80th percentile of 263 medical providers in Utah.

See all medical providers in Utah

Medicare billing

Part B allowed, 2024
$174,234
Medicare patients
399
Services billed
1,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl28$20,713
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen677$20,043
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen462$13,239
Oxycodone Hcl549$12,187
Fentanyl78$11,078
Morphine Sulfate ErMorphine Sulfate361$9,096
MovantikNaloxegol Oxalate15$6,286
Pregabalin251$4,724
Gabapentin327$3,828
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$3,371
Buprenorphine Hcl24$1,650
Celecoxib39$1,268
Methadone Hcl98$1,118
Morphine Sulfate25$1,024
Tramadol Hcl110$1,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$61$20,71328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 263 medical providers in Utah.

Other medical in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →